Review
Accepted on 02 Apr 2025
Tissue-Resident Immune Cells in Cervical Cancer: Emerging Roles and Therapeutic Implications
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1541950
Type at least 3 characters
7,442 articles
Original Research
Accepted on 02 Apr 2025
Ubiquitination and ALL: Identifying FBXO8 as a Prognostic Biomarker and Therapeutic Target
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1554231
Case Report
Accepted on 02 Apr 2025
SMARCA4-deficient NSCLC treated with first-line Tislelizumab and Fruquintinib achieved remarkable tumor regression: Case Report and Literature review
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1521828
Methods
Accepted on 02 Apr 2025
SAPrIm 2.0: A semi-automated protocol for midthroughput soluble HLA immunopeptidomics
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1546629
Mini Review
Accepted on 02 Apr 2025
Enhancing the Physiological Characteristics of Chimeric Antigen Receptor Natural Killer Cells by Synthetic Biology
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1592121
Review
Accepted on 02 Apr 2025
Neutrophil extracellular traps in diseases of the female reproductive organs
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1589329
Case Report
Accepted on 02 Apr 2025
Monoclonal gammopathy-associated C3 glomerulonephritis secondary to follicular lymphoma: a case report
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1551788
Original Research
Accepted on 02 Apr 2025
Neutrophil-to-lymphocyte ratio predicts a poor prognosis for penile cancer with an immunosuppressive tumor microenvironment
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1568825
Review
Published on 02 Apr 2025
Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1572821
- 214 views
Original Research
Published on 02 Apr 2025
Metabolomic machine learning-based model predicts efficacy of chemoimmunotherapy for advanced lung squamous cell carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1545976
- 322 views
Systematic Review
Published on 02 Apr 2025
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1573834
- 185 views
Review
Published on 02 Apr 2025
Where lung cancer and tuberculosis intersect: recent advances
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1561719
- 166 views
Mini Review
Published on 02 Apr 2025
Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1581098
- 182 views
Case Report
Accepted on 01 Apr 2025
Exploring Delayed Hyperprogressive Disease: A Case Study of Post-Immunotherapy in Lung Cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1552547
Review
Accepted on 01 Apr 2025
Nervous system-gut microbiota-immune system axis: Future directions for preventing tumor
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1535955
- 530 views
Review
Accepted on 01 Apr 2025
Identification of B cell antigens in solid cancer: Initial insights and functional implications
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1571570